PRODUCT CODE: em1701-17

PD1 Blocking Monoclonal Antibody (EM1701-17)

Applications

  • ELISA

  • FC

REACTIVITY

  • Human

Flow cytometric analysis of Jurkat cells with PD1 blocking antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
  • Flow cytometric analysis of Jurkat cells with PD1 blocking antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
  • Blockade of Receptor-ligand Interaction at the cellular level using PD1 transfected CHO cells. In a functional ELISA, 50ng of PD1 antibody will block 52% of the binding of PD-L1-Fc to PD1 transfected CHO cells.
Flow cytometric analysis of Jurkat cells with PD1 blocking antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).

Applications

  • ELISA

  • FC

REACTIVITY

  • Human

SPECIFICATIONS

Product Type

Mouse monoclonal primary

Product Name

PD1 Blocking Monoclonal Antibody (EM1701-17)

Immunogen

Recombinant protein

Host

Mouse

Positive Control

Jurkat.

Conjugation

Unconjugated

Clonality

Monoclonal

Clone Number

3A11

PROPERTIES

Form

Liquid

Storage Condition

Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.

Storage Buffer

1*PBS (pH7.4), 0.2% BSA, 50% Glycerol. Preservative: 0.05% Sodium Azide.

Concentration

2 ug/ul

PURIFICATION

Protein G purified.

MOLECULAR WEIGHT

32 kDa

Isotype

IgG1

APPLICATION DILUTION

  • ELISA

  • 1:1,000-1:5,000

  • FC

  • 1:50-1:100

TARGET

UNIPROT #

PROTEIN NAME

Programmed cell death protein 1

GENE NAME

PDCD1

DEVELOPMENTAL STAGE

Induced at programmed cell death.

POST-TRANSLATIONAL MODIFICATION

Ubiquitinated at Lys-233 by the SCF(FBXO38) complex, leading to its proteasomal degradation. Ubiquitinated via 'Lys-48'-linked polyubiquitin chains.; Tyrosine phosphorylated at Tyr-223 (within ITIM motif) and Tyr-248 (ITSM motif) upon ligand binding. Phosphorylation at Tyr-248 promotes the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta.; N-glycosylation at Asn-58 consists of two N-acetylglucosamine units and one fucose. N-glycosylation does not affect binding to nivolumab drug.

SUBCELLULAR LOCATION

Cell membrane; Single-pass type I membrane protein.

FUNCTION

Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (By similarity).; The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy.